[The advantages of Reprimum therapy in pulmonary sarcoidosis and other granulomatous diseases].

C Anastasatu, A Albu, D Burnea, C Didilescu, V Gîrlonţa, P Mihălţan, N Popescu, A Savu, S Udrea, E Păunescu
{"title":"[The advantages of Reprimum therapy in pulmonary sarcoidosis and other granulomatous diseases].","authors":"C Anastasatu,&nbsp;A Albu,&nbsp;D Burnea,&nbsp;C Didilescu,&nbsp;V Gîrlonţa,&nbsp;P Mihălţan,&nbsp;N Popescu,&nbsp;A Savu,&nbsp;S Udrea,&nbsp;E Păunescu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In sarcoidosis and other granulomatous non-caseous diseases, the election treatment is immunosuppressive, mainly with cortisones that ensure more than 70% lasting remissions. Continuous use of cortisones for a long time (8-30 months) in high doses leads to serious side effects: gastric and intestinal ulcers, obesity, osteoporosis, suprarenal dysfunction, sensitivity to infections. Good results and elimination of the important side effects were obtained by treatment with Reprimum--a semisynthetic antibiotic with a wide spectrum and immunosuppressive properties--administered alone or with prednisone in small doses (15-20 mg once) in 6 weeks' series: 2 weeks--Reprimum 10/mg/kg daily +/- prednisone and for other 4 weeks--Reprimum 15 mg/kg twice a week +/- prednisone followed by two weeks' break. In 75 patients with histopathologically confirmed sarcoidosis (of whom 7-9.3% with outside-the-lung situs, too), the treatment with Reprimum gave: 94.7% lasting remission, only 5.3% failures, reduction of the treatment period to 6-12 months and the absence of any important side reaction. In other 37 sarcoidosis cases, failures of cortisone therapy (of which 11-30% relapses after 2-6 years), the treatment with Reprimum together with prednisone allowed recovery of 29 patients (78.4%). The same treatment with Reprimum, used in 22 patients with immunosuppressive treatment indication (dermatomyositis, Kaposi's syndrome, thrombocytopenias, nodose periarteritis, silicosis), of whom 18 (81.8%) were failures of the cortisone therapy, healed 20 of these cases (90.9%). Reprimum immunosuppressive property acts at the level of T4+ lymphocyte, involved in sarcoidosis pathogenesis. The functional blockage of T4+ lymphocyte can be also achieved by cyclosporine A.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":76439,"journal":{"name":"Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia","volume":"38 3","pages":"259-64"},"PeriodicalIF":0.0000,"publicationDate":"1989-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In sarcoidosis and other granulomatous non-caseous diseases, the election treatment is immunosuppressive, mainly with cortisones that ensure more than 70% lasting remissions. Continuous use of cortisones for a long time (8-30 months) in high doses leads to serious side effects: gastric and intestinal ulcers, obesity, osteoporosis, suprarenal dysfunction, sensitivity to infections. Good results and elimination of the important side effects were obtained by treatment with Reprimum--a semisynthetic antibiotic with a wide spectrum and immunosuppressive properties--administered alone or with prednisone in small doses (15-20 mg once) in 6 weeks' series: 2 weeks--Reprimum 10/mg/kg daily +/- prednisone and for other 4 weeks--Reprimum 15 mg/kg twice a week +/- prednisone followed by two weeks' break. In 75 patients with histopathologically confirmed sarcoidosis (of whom 7-9.3% with outside-the-lung situs, too), the treatment with Reprimum gave: 94.7% lasting remission, only 5.3% failures, reduction of the treatment period to 6-12 months and the absence of any important side reaction. In other 37 sarcoidosis cases, failures of cortisone therapy (of which 11-30% relapses after 2-6 years), the treatment with Reprimum together with prednisone allowed recovery of 29 patients (78.4%). The same treatment with Reprimum, used in 22 patients with immunosuppressive treatment indication (dermatomyositis, Kaposi's syndrome, thrombocytopenias, nodose periarteritis, silicosis), of whom 18 (81.8%) were failures of the cortisone therapy, healed 20 of these cases (90.9%). Reprimum immunosuppressive property acts at the level of T4+ lymphocyte, involved in sarcoidosis pathogenesis. The functional blockage of T4+ lymphocyte can be also achieved by cyclosporine A.(ABSTRACT TRUNCATED AT 250 WORDS)

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[复明治疗肺结节病及其他肉芽肿性疾病的优势]。
在结节病和其他非干酪性肉芽肿性疾病中,首选治疗是免疫抑制,主要使用可的松,可确保70%以上的持久缓解。长期(8-30个月)高剂量持续使用可的松会导致严重的副作用:胃溃疡和肠道溃疡、肥胖、骨质疏松、肾上功能障碍、对感染敏感。在6周的系列治疗中,使用remum(一种具有广谱和免疫抑制特性的半合成抗生素)单独或与强的松一起小剂量(15- 20mg一次)治疗获得了良好的效果和消除了重要的副作用:2周- remum每天10/mg/kg +/-强的松,其他4周- remum 15 mg/kg每周两次+/-强的松,然后休息两周。在75例经组织病理学证实的结节病患者中(其中7-9.3%也有肺外病变),reremum治疗的结果是:94.7%的患者持续缓解,只有5.3%的患者失败,治疗时间缩短至6-12个月,没有任何重要的副反应。在其他37例结节病患者中,可的松治疗失败(其中11-30%在2-6年后复发),复康联合强的松治疗使29例患者(78.4%)恢复。在22例免疫抑制治疗指征(皮肌炎、卡波济综合征、血小板减少症、结节性动脉周炎、矽肺)患者中(其中18例(81.8%)可的松治疗失败),使用相同的治疗方法,治愈了其中20例(90.9%)。原发性免疫抑制作用于T4+淋巴细胞水平,参与结节病的发病机制。环孢素a也可实现对T4+淋巴细胞的功能性阻断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Reasons for delayed diagnosis of pulmonary tuberculosis]. [Surveillance of ventilation functions in collectives occupationally exposed to the risk of COPD]. [Should therapeutic pneumothorax really be reconsidered in the treatment of pulmonary tuberculosis? A case report]. [The means for evaluating and optimizing antitubercular chemotherapy as a measure to prevent and combat tuberculosis in county territory]. [Organizational problems of tuberculosis treatment in a rural area].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1